Predictors of infliximab failure after azathioprine withdrawal in crohn's disease treated with combination therapy

American Journal of Gastroenterology

Volumn 105, Issue 5, 2010, Pages 1142-1149

  Oussalah, Abderrahim ^a   Chevaux, Jean Baptiste ^a   Fay, Renaud ^b   Sandborn, William J ^c   Bigard, Marc André ^a   Peyrin Biroulet, Laurent ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b Ctr Hospitalier Univ de Nancy   (France)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; INFLIXIMAB;

ADULT; ANAPHYLACTIC SHOCK; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PSORIASIS; RELAPSE; REMISSION; SERUM SICKNESS; SURVIVAL; TREATMENT FAILURE;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; COHORT STUDIES; CONFIDENCE INTERVALS; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 77951977369     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.158     Document Type: Article

References (25)

1. Prefontaine E, Sutherland LR, Macdonald JK et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009, CD000067.
2. Peyrin-Biroulet L, Deltenre P, de Suray N et al. Effi cacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6: 644-653
3. Stange EF, Travis SP, Vermeire S et al. European evidence based consensus on the diagnosis and management of Crohn's disease: defi nitions and diagnosis. Gut 2006; 55 (Suppl 1): i1-15.
4. Toruner M, Loft us EV Jr, Harmsen WS et al. Risk factors for opportunistic infections in patients with infl ammatory bowel disease. Gastroenterology 2008; 134: 929-936
5. Shale M, Kanfer E, Panaccione R et al. Hepatosplenic T cell lymphoma in infl ammatory bowel disease. Gut 2008; 57: 1639-1641
6. Mackey AC, Green L, Leptak C et al. Hepatosplenic T cell lymphoma associated with infl iximab use in young patients treated for infl ammatory bowel disease: update. J Pediatr Gastroenterol Nutr 2009; 48: 386-388
7. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104: 465-483
8. Sandborn WJ, Rutgeerts PJ, Reinisch W et al. One year data from the Sonic study: A randomized, double-blind trial comparing infl iximab and infl iximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology 2009; 136: A116.
9. Van Assche G, Magdelaine-Beuzelin C, D'Haens G et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infl iximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-1868
10. Satsangi J, Silverberg MS, Vermeire S et al. The Montreal classifi cation of infl ammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-753
11. Oussalah A, Babouri A, Chevaux JB et al. Adalimumab for Crohn's disease with intolerance or lost response to infl iximab: a 3-year single-centre experience. Aliment Pharmacol Ther 2009; 29: 416-423
12. Deshpande AR, Abreu MT. Combination therapy with infl iximab and immunomodulators: is the glass half empty? Gastroenterology 2008; 134: 2161-2163
13. Baert F, Noman M, Vermeire S et al. Infl uence of immunogenicity on the longterm effi cacy of infl iximab in Crohn's disease. N Engl J Med 2003; 348: 601-608
14. Vermeire S, Noman M, Van Assche G et al. Eff ectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infl iximab in Crohn's disease. Gut 2007; 56: 1226-1231
15. Rutgeerts P, Diamond RH, Bala M et al. Scheduled maintenance treatment with infl iximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006; 63: 433-442
16. Rutgeerts P, Feagan BG, Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of infl iximab in Crohn's disease. Gastroenterology 2004; 126: 402-413
17. Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infl iximab aft er maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 542-553
18. Maser EA, Villela R, Silverberg MS et al. Association of trough serum infl iximab to clinical outcome aft er scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1248-1254
19. Lichtenstein GR, Diamond RH, Wagner CL et al. Clinical trial: benefi ts and risks of immunomodulators and maintenance infl iximab for IBDsubgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009; 30: 210-226
20. Siegel CA, Marden SM, Persing SM et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009; 7: 874-881
21. Louis E, Vernier-Massouille G, Grimaud J-C et al. Infl iximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: a prospective ongoing cohort study. Gastroenterology 2009; 136: A146.
22. Treton X, Bouhnik Y, Mary JY et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009; 7: 80-85
23. Cassinotti A, Actis GC, Duca P et al. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors aft er drug withdrawal. Am J Gastroenterol 2009; 104: 2760-2767
24. Sokol H, Seksik P, Nion-Larmurier I et al. Withdrawal of immunosuppression in infl ammatory bowel disease treated with infl iximab maintenance therapy. Gastroenterology 2009; 136: A-187-188
25. Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infl iximab: a randomized trial. Ann Intern Med 2007; 146: 829-838